This segment focuses on the research, development, and clinical trials of ANEB-001, a small molecule cannabinoid receptor antagonist. ANEB-001 is designed to treat acute cannabinoid intoxication and overdose, addressing a significant unmet medical need. The company utilizes advanced pharmaceutical research and development methodologies, including preclinical studies and clinical trials, to evaluate the safety and efficacy of ANEB-001. The primary therapeutic area is substance abuse, specifically the adverse effects of cannabis use. The patient impact is aimed at reducing the severity of symptoms and improving outcomes for individuals experiencing cannabinoid-induced adverse events. Anebulo aims to establish a strong market position by offering a first-in-class treatment. Future opportunities include expanding the application of ANEB-001 to other substance abuse disorders. Regulatory and clinical aspects involve navigating FDA approval processes and conducting Phase 2 and potentially Phase 3 clinical trials. The company may seek partnerships with hospitals, emergency departments, and addiction treatment centers to facilitate clinical trials and commercialization.